Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant...
Designed to reduce the operational burden that stands between physicians and their patients. Initial offering focuses on pre-surgery cataract education, with additional AI capabilities...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July...
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
Among dry eye sufferers who said their stress or anxiety levels were affected, most (73%) reported improvement following treatment While some sufferers (22%) were aware that dry eye symptoms...
3 Small-Cap Stocks We Steer Clear Of
1 Stock Under $50 to Own for Decades and 2 We Turn Down
Blink Triple Care Preservative Free eye drops are made with the same clinically proven formula as Blink Triple Care and provide up to 10 hours of dry eye symptom relief‡ ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical...